Hong Kong REITS Stock News

As global markets navigate a mixed landscape, with major U.S. indices like the Nasdaq Composite and S&P 500 showing gains while small-cap indices such as the Russell 2000 decline, investors are closely monitoring economic indicators that suggest a cooling labor market and subdued consumer confidence. In this environment, characterized by fluctuating treasury yields and varying sector performances, identifying high-growth tech stocks requires a focus on companies that demonstrate resilience...

As global markets experience mixed performances, with the U.S. labor market showing signs of cooling and China's manufacturing activity indicating resilience, investors are closely watching the Asian tech sector for high-growth opportunities. In this environment, a good stock in the high-growth tech space is often characterized by strong fundamentals and adaptability to shifting economic conditions, making Damai Entertainment Holdings a notable player in Asia's dynamic market landscape.

As of July 2026, Asian markets are navigating a complex landscape shaped by mixed economic signals and sector rotations. Amid these evolving conditions, investors are increasingly exploring opportunities in lesser-known segments of the market. Penny stocks, though an outdated term, still capture the essence of investing in smaller or emerging companies that can offer significant value when backed by strong financials and growth potential.

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

China International Capital Corporation Limited has approved a final cash dividend of RMB 2.3 per 10 shares (HK$2.644632 per 10 shares) for the year ended 31 December 2025, with shareholder approval obtained on 26 June 2026 and payment scheduled for 24 August 2026. This higher final cash dividend highlights how the firm is prioritising direct cash returns to shareholders at this stage of its capital allocation. Next, we will examine how this higher final cash dividend shapes China...

As Asian markets navigate a period of mixed performance, with China's manufacturing activity showing resilience and Japan's business sentiment improving, investors are keenly observing opportunities that may be flying under the radar. In such an environment, identifying undervalued stocks requires a keen understanding of market dynamics and the ability to recognize companies with strong fundamentals that may not yet be fully appreciated by the broader market.

New World Development (SEHK:17) is back in focus after strong unit sales at its Pavilia Rosa project in Kowloon Tong, along with a same day surge in ultra large institutional buy orders. See our latest analysis for New World Development. At a share price of HK$6.58, New World Development has a 1 day share price return of 4.78% but is still down 14.43% over 30 days and 17.23% over 90 days. The 1 year total shareholder return of 19.64% contrasts with a 5 year total shareholder return that has...

Crypto linked stocks are back in focus as Kevin Warsh’s comments on easing inflation, rising crypto asset prices, and mixed ETF flows pull attention toward companies most exposed to Bitcoin, Ethereum and other tokens. While spot Bitcoin ETFs are seeing outflows of US$296 million and Ethereum products are attracting fresh inflows, Solana and other major cryptos are drawing interest from investors looking for potential long term utility. This article explains how that mix of signals could...

Want Want China Holdings (SEHK:151) is back in focus after releasing full year results to March 31, 2026, together with a proposed lower final ordinary dividend, putting profitability and cash returns to shareholders under the spotlight. See our latest analysis for Want Want China Holdings. The latest earnings and dividend update appears to have sharpened attention on Want Want China Holdings' profitability, with the stock closing at HK$3.24 and a 1-day share price return of 2.53% following a...

Hansoh Pharmaceutical Group (SEHK:3692) has received approval from China's National Medical Products Administration to start clinical trials of its HS-20136-2 injection for type 2 diabetes and obesity, drawing fresh attention to the stock. See our latest analysis for Hansoh Pharmaceutical Group. The clinical trial approval arrives after a sharp swing in sentiment, with Hansoh Pharmaceutical Group’s share price up 17.59% over the past week and 13.09% over 30 days, even though the 90 day share...

Investors who take an interest in AK Medical Holdings Limited ( HKG:1789 ) should definitely note that the VP...

Genertec Universal Medical Group (SEHK:2666) drew investor focus after its annual general meeting on 24 June 2026, where shareholders approved a final dividend of HK$0.36 per share and amendments to the company’s articles of association. See our latest analysis for Genertec Universal Medical Group. At a share price of HK$4.62, Genertec Universal Medical Group has seen short term share price returns pick up, with gains of 3.36% over one day and 5.24% over seven days. However, the 30 day share...

JD Health International Inc. ( HKG:6618 ) saw a double-digit share price rise of over 10% in the past couple of months...

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Alebund Pharmaceuticals (Jiangsu) (SEHK:9637) has just completed a HK$1.28b IPO in Hong Kong, an event that brings new attention to its kidney disease drug pipeline and newly listed H shares. See our latest analysis for Alebund Pharmaceuticals (Jiangsu). The strong first day reception for Alebund Pharmaceuticals (Jiangsu) has been followed by a 1 day share price return of 18.75% to HK$30.28, although the share price return year to date is down 34.17%. This suggests short term momentum is...

COSCO SHIPPING Ports Limited ( HKG:1199 ), might not be a large cap stock, but it saw significant share price movement...

Legendary Education Group Limited's ( HKG:8195 ) recent earnings report didn't offer any surprises, with the shares...

Despite posting healthy earnings, China High Speed Transmission Equipment Group Co., Ltd.'s ( HKG:658 ) stock has been...

As you might know, China Water Affairs Group Limited ( HKG:855 ) recently reported its full-year numbers. Statutory...

It looks like China Taiping Insurance Holdings Company Limited ( HKG:966 ) is about to go ex-dividend in the next four...

CARsgen Therapeutics Holdings announced that China’s National Medical Products Administration has approved satricabtagene autoleucel (satri-cel), an autologous Claudin18.2-targeted CAR T-cell therapy, for Claudin18.2-positive, HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma in patients who have failed at least two prior treatments. As the first CAR T-cell therapy approved globally for solid tumors, satri-cel could reshape treatment options in high-burden cancers like...

With inflation trends uneven across regions and central banks sending mixed signals on rate paths, dependable income can feel hard to find. That is where the Dividend Powerhouses screener comes in, focusing on companies with dividend yields above 5% that are covered by current earnings, growing and relatively stable. While policy debates continue around interest rates, growth and inflation, these stocks aim to put cash in your account today. In this article, you will see three stocks from the...